Chronic Urticaria companies working in the market are Sanofi-Aventis, Merck & Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, and others.

(Albany, USA) DelveInsight's "Chronic Urticaria Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Urticaria, historical and forecasted epidemiology as well as the Chronic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Urticaria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Urticaria market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Urticaria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Urticaria market.

Request for a Free Sample Report @ Chronic Urticaria Market Forecast

Some facts of the Chronic Urticaria Market Report are:

*According to DelveInsight, Chronic Urticaria market size is expected to grow at a decent CAGR by 2032. *Leading Chronic Urticaria companies working in the market are Sanofi-Aventis, Merck & Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, and others. *Key Chronic Urticaria Therapies expected to launch in the market are Fexofenadin, Omalizumab, Desloratadine, Levocetirizine, Dupilumab, Rilzabrutinib, Remibrutinib, Benralizumab, Legelizumab, and many others. *In March 2025, Novartis announced results of a 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines *In February 2025, Celldex Therapeutics announced results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1) *In January 2025, Novartis announced results of a Real-world, Prospective, Multicenter Study of Safety and Effectiveness of Xolair® (Omalizumab) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Chinese Adolescents Inadequately Controlled With H1 Antihistamines *In March 2025, Jiangsu Hansoh Pharmaceutical Co., Ltd. announced results of a Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. *In December 2024, Incyte Corporation announced results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria *In November 2024, Jasper Therapeutics, Inc announced results of a Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines *In May 2024, the culmination of a 52-week trial provided compelling evidence for the favourable safety profile of remibrutinib, a promising pharmaceutical compound. This extended study period is crucial, as it allows for a thorough assessment of a drug's long-term tolerability. *In February 2024, Sanofi's experimental drug, rilzabrutinib, has shown promising results in a Phase II clinical trial for patients with chronic spontaneous urticaria, a condition marked by persistent hives and intense itching.

Chronic Urticaria Overview

Chronic Urticaria is a persistent skin disorder characterized by the recurrent appearance of itchy, raised, and swollen welts (hives) that last for more than six weeks. It can be classified into chronic spontaneous urticaria (CSU), which occurs without an identifiable trigger, and chronic inducible urticaria (CIndU), which is triggered by specific stimuli such as pressure, heat, cold, or sunlight. The condition is caused by the excessive release of histamine and other inflammatory mediators from mast cells and basophils, leading to itching, swelling, and discomfort.

The exact cause of Chronic Urticaria remains unclear, but it is often linked to autoimmune conditions, infections, allergic reactions, and stress. Diagnosis primarily involves clinical evaluation, patient history, and allergy testing, while treatment focuses on symptom management. Second-generation antihistamines like fexofenadine and desloratadine are the first-line treatment, while biologics such as omalizumab and emerging therapies like Bruton's tyrosine kinase (BTK) inhibitors offer advanced options for refractory cases.

The increasing prevalence of allergic disorders and autoimmune diseases, along with advancements in targeted biologics and immunotherapies, is driving growth in the chronic urticaria treatment market. Research continues to focus on novel therapies to improve long-term symptom control and patient quality of life.

Learn more about Chronic Urticaria treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Chronic Urticaria Treatment Market

Chronic Urticaria Market

The Chronic Urticaria market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Urticaria market trends by analyzing the impact of current Chronic Urticaria therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic Urticaria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Urticaria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic Urticaria market in 7MM is expected to witness a major change in the study period 2019-2032.

Chronic Urticaria Epidemiology

The Chronic Urticaria epidemiology section provides insights into the historical and current Chronic Urticaria patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chronic Urticaria market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Chronic Urticaria Epidemiology @ Chronic Urticaria Prevalence

Chronic Urticaria Drugs Uptake

This section focuses on the uptake rate of the potential Chronic Urticaria drugs recently launched in the Chronic Urticaria market or expected to be launched in 2019-2032. The analysis covers the Chronic Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chronic Urticaria Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chronic Urticaria market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Urticaria Pipeline Development Activities

The Chronic Urticaria report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chronic Urticaria key players involved in developing targeted therapeutics.

Marketed Therapies in the Chronic Urticaria Market

Fexofenadine - Sanofi

Fexofenadine, sold under the brand name Allegra by Sanofi, is a second-generation antihistamine widely used for managing allergic conditions, including Chronic Urticaria (CU). It works by selectively blocking H1 histamine receptors, preventing histamine from triggering itching, swelling, and hives, which are hallmark symptoms of CU.

Desloratadine - Merck & Co

Desloratadine, a well-known second-generation antihistamine, is marketed under the brand name Clarinex by Merck & Co. It is commonly prescribed for Chronic Urticaria (CU) due to its proven efficacy in reducing persistent and distressing hives.

Xolair (omalizumab) - Roche/Novartis

Xolair (omalizumab), co-developed by Roche and Novartis, is a monoclonal antibody therapy that has revolutionized the treatment of Chronic Urticaria (CU), particularly for chronic spontaneous urticaria (CSU) cases that do not respond to standard treatments like antihistamines and corticosteroids.

Emerging Therapies in the Chronic Urticaria Market

Rilzabrutinib - Sanofi

Rilzabrutinib, an investigational therapy developed by Principia Biopharma (a subsidiary of Sanofi), is a promising candidate for Chronic Urticaria (CU) treatment. It is a Bruton's tyrosine kinase (BTK) inhibitor, a drug class known for its role in modulating immune cell activity and reducing inflammatory responses.

Remibrutinib - Novartis

Remibrutinib, an investigational BTK inhibitor developed by Novartis, is being studied for its potential in treating Chronic Urticaria (CU), particularly chronic spontaneous urticaria (CSU). BTK is a crucial enzyme involved in the immune signaling pathways of mast cells, basophils, and B cells, which drive the inflammatory processes in urticaria.

Request for a sample report to understand more about the Chronic Urticaria pipeline development activities @ Chronic Urticaria Clinical Trials and Therapeutic Advancements

Chronic Urticaria Therapeutics Assessment

Major key companies are working proactively in the Chronic Urticaria Therapeutics market to develop novel therapies which will drive the Chronic Urticaria treatment markets in the upcoming years are Sanofi-Aventis, Merck & Co., UCB, Regeneron, Roche, Principia Biopharma, Novartis, AstraZeneca, Kyowa Kirin, and others.

Learn more about the emerging Chronic Urticaria therapies & key companies @ Hyperhidriosis Drugs Market

Chronic Urticaria Report Key Insights

1. Chronic Urticaria Patient Population

2. Chronic Urticaria Market Size and Trends

3. Key Cross Competition in the Chronic Urticaria Market

4. Chronic Urticaria Market Dynamics (Key Drivers and Barriers)

5. Chronic Urticaria Market Opportunities

6. Chronic Urticaria Therapeutic Approaches

7. Chronic Urticaria Pipeline Analysis

8. Chronic Urticaria Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chronic Urticaria Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Chronic Urticaria Competitive Intelligence Analysis

4. Chronic Urticaria Market Overview at a Glance

5. Chronic Urticaria Disease Background and Overview

6. Chronic Urticaria Patient Journey

7. Chronic Urticaria Epidemiology and Patient Population

8. Chronic Urticaria Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Urticaria Unmet Needs

10. Key Endpoints of Chronic Urticaria Treatment

11. Chronic Urticaria Marketed Products

12. Chronic Urticaria Emerging Therapies

13. Chronic Urticaria Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Urticaria Market Outlook (7 major markets)

16. Chronic Urticaria Access and Reimbursement Overview

17. KOL Views on the Chronic Urticaria Market

18. Chronic Urticaria Market Drivers

19. Chronic Urticaria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +14699457679

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/consulting

Source: www.abnewswire.com